Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Boehringer Ingelheim
Merck
McKinsey
Deloitte
Accenture
Colorcon
US Army
Argus Health

Generated: May 23, 2018

DrugPatentWatch Database Preview

Oxybutynin - Generic Drug Details

or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for oxybutynin and what is the scope of oxybutynin freedom to operate?

Oxybutynin
is the generic ingredient in eight branded drugs marketed by Barr Labs Div Teva, Allergan Sales Llc, Ortho Mcneil Janssen, Apotex Inc, Lannett Co Inc, Mikart, Pharm Assoc, Vintage Pharms, Wockhardt Bio Ag, Janssen Pharms, Accord Hlthcare, Amneal Pharms, Impax Pharms, Mylan, Mylan Pharms Inc, Osmotica Pharm Us, Unique Pharm Labs, Zydus Pharms Usa Inc, Abhai Llc, Appco Pharma Llc, Novitium Pharma, Quantum Pharmics, Teva Pharms Usa, Upsher-smith Labs, Usl Pharma, and Watson Labs, and is included in thirty-one NDAs. There are eleven patents protecting this compound and one Paragraph IV challenge. Additional information is available in the individual branded drug profile pages.

Oxybutynin has one hundred and fifteen patent family members in twenty-two countries.

There are sixteen drug master file entries for oxybutynin. Two suppliers are listed for this compound.
Pharmacology for oxybutynin
Synonyms for oxybutynin
(+/-)-oxybutynin
(+/-)-OXYBUTYNIN(Hydrochloride form)
1508-65-2 (hydrochloride)
27815-EP2269989A1
27815-EP2275420A1
27815-EP2280008A2
27815-EP2298767A1
27815-EP2314587A1
4-(Diethylamino)-2-butynyl .alpha.-phenylcyclohexaneglycolate
4-(Diethylamino)-2-butynyl alpha-phenylcyclohexaneglycolic acid ester
4-(Diethylamino)-2-butynyl cyclohexyl(hydroxy)phenylacetate #
4-(diethylamino)-2-butynyl-alpha-cyclohexyl-alpha-hydroxybenzeneacetate
4-(diethylamino)-2-butynyl-alpha-phenylcyclohexaneglycolate
4-(diethylamino)but-2-yn-1-yl 2-cyclohexyl-2-hydroxy-2-phenylacetate
4-(diethylamino)but-2-yn-1-yl cyclohexyl(hydroxy)phenylacetate
4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenyl-acetate
4-(diethylamino)but-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
4-Diethylamino-2-butinyl alpha-cyclohexylmandelat
4-Diethylamino-2-butynyl alpha-phenylcyclohexaneglycolate
4-diethylaminobut-2-ynyl 2-cyclohexyl-2-hydroxy-2-phenylacetate
5633-20-5
633O205
AB0013281
AB2000274
AC-2153
AC1L1ILV
AK162584
AKOS015896242
AN-14276
Anturol
Anturol (TN)
API0007236
AX8146542
BDBM50165019
Benzeneacetic acid, alpha-cyclohexyl-alpha-hydroxy-, 4-(diethylamino)-2-butynyl ester
BPBio1_000214
BRD-A65013509-003-03-8
BSPBio_000194
C-20821
C07360
CC-33425
CCG-205005
CCRIS 1923
CHEBI:7856
CHEMBL1231
CS-2255
Cyclohexaneglycolic acid, .alpha.-phenyl-, 4-(diethylamino)-2-butynyl ester
Cyclohexaneglycolic acid, alpha-phenyl-, 4-(diethylamino)-2-butynyl ester
Cystrin
D00465
D0F5LH
DB01062
Ditropan
Ditropan Xl
Ditropan;Lyrinel XL;Oxytrol
DR001867
DTXSID0023406
FT-0082890
FT-0603679
GTPL359
HSDB 3270
HY-B0267
I06-2117
K-9978
kentera
KS-00000GVI
KS-5221
L000923
Lopac0_000923
LP048773
LS-28714
Lyrinel XL
MCULE-3407007074
MFCD00865252
MLS006010052
MolPort-003-849-741
MRF-0000601
NCGC00015767-03
NCGC00015767-04
NCGC00015767-06
NCGC00015767-07
NCGC00015767-09
NCGC00089795-02
O222
OR285581
Oxibutinina
Oxibutinina [INN-Spanish]
Oxibutyninum
Oxybutinin
Oxybutynin (Ditropan)
Oxybutynin (USAN/INN)
Oxybutynin [USAN:INN:BAN]
Oxybutynin Base
oxybutynin topical gel
Oxybutynin transdermal
Oxybutynin transdermal patch
OXYBUTYNIN, Oxybutynin chloride
Oxybutynine
Oxybutynine [INN-French]
Oxybutyninum
Oxybutyninum [INN-Latin]
Oxytrol
Oxytrol (TN)
Pollakisu
Prestwick0_000287
Prestwick1_000287
Prestwick2_000287
Prestwick3_000287
s1754
SBI-0050898.P002
SC-26752
SCHEMBL2992
SMR001550466
SPBio_002413
ST24048863
transdermal patch
XIQVNETUBQGFHX-UHFFFAOYSA-N

US Patents and Regulatory Information for oxybutynin

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms Usa Inc OXYBUTYNIN CHLORIDE oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 202332-001 Jun 26, 2017 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Osmotica Pharm Us OXYBUTYNIN CHLORIDE oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 078503-002 Feb 4, 2009 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Unique Pharm Labs OXYBUTYNIN CHLORIDE oxybutynin chloride TABLET, EXTENDED RELEASE;ORAL 206121-002 May 27, 2016 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Quantum Pharmics OXYBUTYNIN CHLORIDE oxybutynin chloride TABLET;ORAL 072296-001 Dec 8, 1988 DISCN No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

Expired US Patents for oxybutynin

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc OXYTROL oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 021351-002 Feb 26, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 ➤ Try a Free Trial ➤ Try a Free Trial
Allergan Sales Llc OXYTROL FOR WOMEN oxybutynin FILM, EXTENDED RELEASE;TRANSDERMAL 202211-001 Jan 25, 2013 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for oxybutynin

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,980,309 Transdermal testosterone formulation for minimizing skin residues ➤ Try a Free Trial
7,087,241 Compositions and methods for minimizing adverse drug experiences associated with oxybutynin therapy ➤ Try a Free Trial
7,335,379 Transdermal pharmaceutical formulation for minimizing skin residues ➤ Try a Free Trial
7,214,381 Composition for transdermal and/or transmucosal administration of active compounds that ensures adequate therapeutic levels ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

or, see our see our flat-rate plans

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKinsey
Teva
Federal Trade Commission
Cantor Fitzgerald
US Department of Justice
AstraZeneca
Chinese Patent Office
Covington
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.